SAN DIEGO, March 21, 2022 (GLOBE NEWSWIRE) — Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) under Subpart H for accelerated approval of…Original Article
Travere Therapeutics Submits New Drug Application for Sparsentan for the Treatment of IgA Nephropathy
